Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

[1] Allegra CJ(2009)American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2091-2096

[2] Jessup JM(2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634

[3] Somerfield MR(2002)Selection bias in gene extraction on the basis of microarray gene-expression data Proc Natl Acad Sci USA 99 6562-6566

[4] Hamilton SR(2001)Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study Br J Cancer 85 692-696

[5] Hammond EH(2004)Somatic mutations of EGFR in colorectal cancers and glioblastomas N Engl J Med 351 2883-2459

[6] Hayes DF(2005)Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 2445-300

[7] McAllister PK(1995)Controlling the false discovery rate: a practical and powerful approach to multiple testing J Roy Statist Soc B 57 289-2648

[8] Morton RF(2007)Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643-41

[9] Schilsky RL(1982)A confidence interval for the median survival time Biometrics 38 29-723

[10] Amado RG(2008)EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients Ann Oncol 19 717-1810

[1] Allegra CJ(2009)American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2091-2096

[2] Jessup JM(2008)Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634

[3] Somerfield MR(2002)Selection bias in gene extraction on the basis of microarray gene-expression data Proc Natl Acad Sci USA 99 6562-6566

[4] Hamilton SR(2001)Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study Br J Cancer 85 692-696

[5] Hammond EH(2004)Somatic mutations of EGFR in colorectal cancers and glioblastomas N Engl J Med 351 2883-2459

[6] Hayes DF(2005)Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 2445-300

[7] McAllister PK(1995)Controlling the false discovery rate: a practical and powerful approach to multiple testing J Roy Statist Soc B 57 289-2648

[8] Morton RF(2007)Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643-41

[9] Schilsky RL(1982)A confidence interval for the median survival time Biometrics 38 29-723

[10] Amado RG(2008)EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients Ann Oncol 19 717-1810